US firms cash in on active pharmaceutical sector as Valeant agrees deal to acquire Salix’s outstanding stock
February 23, 2015 at 07:41 AM
1 minute read
The original version of this story was published on Legalweek
Sullivan & Cromwell and Cadwalader, Wickersham & Taft are acting as lead advisers on Valeant’s $14.5bn (£9.5bn) acquisition of gastrointestinal drug specialist Salix.
Valeant will pick up all of Salix’s outstanding common stock for $158 (£103) per share in a transaction that will entail the Quebec-based group taking control of Salix’s portfolio of 22 products, including prescription brands Xifaxan, Uceris, and Apriso.
Presented by BigVoodoo
Celebrate outstanding achievement in law firms, chambers, in-house legal departments and alternative business structures.
The African Legal Awards recognise exceptional achievement within Africa s legal community during a period of rapid change.
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
